Open AccessMetformin and statins: a possible role in high-risk prostate cancer
Author(s) -
Giovanna Cadeddu,
Asunción Hervás-Morón,
Marta Martín,
Lira Pelari-Mici,
Kathy Ytuza-Charahua de Kirsch,
Antonio Hernández-Corrales,
Carmen Vallejo-Ocaña,
Sara Sastre-Gallego,
Eliseo Carrasco-Esteban,
S. Sancho-García,
Fernando López-Campos
Publication year - 2020
Publication title -
reports of practical oncology and radiotherapy
Language(s) - English
Resource type - Journals
eISSN - 2083-4640
pISSN - 1507-1367
DOI - 10.1016/j.rpor.2019.12.027
Subject(s) - metformin , medicine , prostate cancer , oncology , androgen deprivation therapy , cancer , prostatectomy , urology , insulin
There is increasing evidence that statins and oral anti-diabetic drugs, such as metformin, can have a favorable role in advanced prostate cancer treatment.Metformin has been shown to inhibit proliferation of tumor cells in vitro and statins inhibit carcinogenesis by suppressing angiogenesis/invasion mechanisms. However, clinical evidence on the protective effect of these drugs is still weak.The purpose of this study is to analyze if these drugs have an impact on Biochemical-Failure-Free-Survival (BFFS) and on Distant-Failure-Free-Survival (DFFS) in localized high-risk prostate cancer.